UCB struck a global licensing agreement with Antengene for ATG‑201, a CD19/CD3 bispecific T‑cell engager designed to deplete pathogenic B cells in autoimmune diseases, with $60 million upfront plus up to $1.1 billion in milestones and tiered royalties. Antengene will lead early trials in China and Australia before UCB assumes global development and commercialization. ATG‑201 leverages Antengene’s AnTenGager platform with steric hindrance masking intended to improve therapeutic index. UCB framed the deal as a strategic expansion into immunology and an inorganic route to bispecific TCE capabilities, aligning with the company’s specialty biologics strategy. Operationally, the agreement accelerates clinical testing for ATG‑201 and signals continued industry appetite for next‑generation immune‑cell engagers in autoimmune indications with significant unmet need.